Biosynthesis and Characterization of Vosoritide by Escherichia coli

Abstract

Vosoritide is a therapeutic peptide that promotes skeletal growth by targeting the NPR-B receptor and was approved in 2021 for the treatment of achondroplasia. However, its high production cost poses a considerable economic burden on patients, limiting its widespread use. This study aims to establish an efficient and cost-effective biosynthetic process for the production of Vosoritide using Escherichia coli. In this work, Vosoritide was expressed as inclusion bodies (IBs) in E. coli BL21 (DE3) via a gp55 fusion strategy. Downstream processes, including fermentation, HCl-induced acidic cleavage of IBs, pH-dependent protein precipitation, as well as the performing conditions of the ion-exchange chromatography and reverse-phase chromatography, were optimized. The analysis methods included sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), high-performance liquid chromatography (HPLC), and liquid chromatography-tandem mass spectrometry. Cyclic guanosine monophosphate (cGMP) assays were conducted to assess the biological activity of the protein in NIH3T3 cells. Vosoritide was obtained at 1.3 g per liter of fermentation broth with a purity exceeding 99%. The peptide's primary structure, molecular weight, and disulfide bond integrity were also confirmed through mass spectrometry and peptide mapping. The purified Vosoritide stimulated cGMP production in NIH3T3 cells with a half-maximal effective concentration (EC₅₀) of 0.37 nmol/L. In conclusion, this study provided a scalable, high-yield production method for Vosoritide that yields Vosoritide with pharmaceutical-grade purity and activity, holding significant potential for manufacturing a cost-effective biosimilar with broader clinical accessibility.

Keywords

Vosoritide - achondroplasia (ACH) - biosimilars - inclusion bodies

• References

• 1 Bellus GA, Hefferon TW, Ortiz de Luna RI. et al. Achondroplasia is defined by recurrent G380R mutations of FGFR3. Am J Hum Genet 1995; 56 (02) 368-373
• 2 FDA News Release. . FDA approves first drug to improve growth in children with most common form of dwarfism. Accessed June 25, 2021 at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-improve-growth-children-most-common-form-dwarfism
• 3 European Medicines Agency. . New treatment for people with dwarfism. Accessed December 11, 2024 at: https://www.ema.europa.eu/en/news/new-treatment-people-dwarfism
• 4 Wrobel W, Pach E, Ben-Skowronek I. Advantages and disadvantages of different treatment methods in achondroplasia: a review. Int J Mol Sci 2021; 22 (11) 5573
• 5 Dauber A, Zhang A, Kanakatti Shankar R. et al. Vosoritide treatment for children with hypochondroplasia: a phase 2 trial. EClinicalMedicine 2024; 71: 102591
• 6 Paraskevopoulou V, Falcone FH. Polyionic tags as enhancers of protein solubility in recombinant protein expression. Microorganisms 2018; 6 (02) 47
• 7 Jiang R, Yuan S, Zhou Y. et al. Strategies to overcome the challenges of low or no expression of heterologous proteins in Escherichia coli . Biotechnol Adv 2024; 75: 108417
• 8 Berrow N, de Marco A, Lebendiker M. et al. Quality control of purified proteins to improve data quality and reproducibility: results from a large-scale survey. Eur Biophys J 2021; 50 (3-4): 453-460
• 9 Liew OW, Ching Chong JP, Yandle TG, Brennan SO. Preparation of recombinant thioredoxin fused N-terminal proCNP: analysis of enterokinase cleavage products reveals new enterokinase cleavage sites. Protein Expr Purif 2005; 41 (02) 332-340
• 10 Long S, Wendt DJ, Bell SM, Taylor TW, Dewavrin JY, Vellard MC. A novel method for the large-scale production of PG-CNP37, a C-type natriuretic peptide analogue. J Biotechnol 2012; 164 (02) 196-201
• 11 Hong H, James G, Zhang Na. , et al. ; Tianjin Asymchem Bio-Tech Co., Ltd. Soluble intermediate of Vosoritide, preparation method of the intermediate, and preparation method of vosoritide [in Chinese]. CN Patent 117801123B. April 2, 2024
• 12 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227 (5259) 680-685
• 13 Gram H, Rüger W. Genes 55, alpha gt, 47 and 46 of bacteriophage T4: the genomic organization as deduced by sequence analysis. EMBO J 1985; 4 (01) 257-264
• 14 Ruan SD, Dong YZ, Lu JG, Zhao MJ, Lu WG, Feng J. Synthesis of a novel PTH1–34 analog with increased human serum albumin affinity. Pharmaceut Fronts 2021; 03 (01) e23-e29
• 15 Gram H, Ramage P, Memmert K, Gamse R, Kocher HP. A novel approach for high level production of a recombinant human parathyroid hormone fragment in Escherichia coli . Biotechnology (N Y) 1994; 12 (10) 1017-1023
• 16 Singha TK, Gulati P, Mohanty A, Khasa YP, Kapoor RK, Kumar S. Efficient genetic approaches for improvement of plasmid based expression of recombinant protein in Escherichia coli: a review. Process Biochem 2017; 55: 17-31
• 17 Tabor S. Expression using the T7 RNA polymerase/promoter system. Curr Protoc Mol Biol 1990; 11 (01) 16.2.1-16.2.11
• 18 Luli GW, Strohl WR. Comparison of growth, acetate production, and acetate inhibition of Escherichia coli strains in batch and fed-batch fermentations. Appl Environ Microbiol 1990; 56 (04) 1004-1011
• 19 Kallberg K, Johansson HO, Bulow L. Multimodal chromatography: an efficient tool in downstream processing of proteins. Biotechnol J 2012; 7 (12) 1485-1495
• 20 Labrou NE. ed Protein downstream processing: design, development, and application of high and low-resolution methods. Vol. 2178. Totowa, NJ: Humana Press; 2021
• 21 Shaik MI, Sarbon NM. A review on purification and characterization of anti-proliferative peptides derived from fish protein hydrolysate. Food Rev Int 2022; 38 (07) 1389-1409
• 22 Åsberg D, Langborg Weinmann A, Leek T. et al. The importance of ion-pairing in peptide purification by reversed-phase liquid chromatography. J Chromatogr A 2017; 1496: 80-91
• 23 Wendt DJ, Dvorak-Ewell M, Bullens S. et al. Neutral endopeptidase-resistant C-type natriuretic peptide variant represents a new therapeutic approach for treatment of fibroblast growth factor receptor 3-related dwarfism. J Pharmacol Exp Ther 2015; 353 (01) 132-149
• 24 Zhu-Shimoni J, Yu C, Nishihara J. et al. Host cell protein testing by ELISAs and the use of orthogonal methods. Biotechnol Bioeng 2014; 111 (12) 2367-2379
• 25 Wang X, Morgan DM, Wang G, Mozier NM. Residual DNA analysis in biologics development: review of measurement and quantitation technologies and future directions. Biotechnol Bioeng 2012; 109 (02) 307-317